WALTHAM, Mass.--(BUSINESS WIRE)--N-of-One Therapeutics, Inc., the leading provider of molecular interpretation and therapeutic strategies for personalized cancer care since 2008, today announced that it has analyzed and interpreted its 4,000th cancer patient tumor, an industry milestone.
“With the growing importance of clinical interpretation we have added and are in discussion with a number of healthcare providers and diagnostics companies to provide clinical interpretation of their next generation sequencing tests”
The challenge of precision medicine is the clinical interpretation of the sequencing data, the millions of clinical research findings, and thousands of clinical trials into available therapeutic options that can be easily utilized by treating physicians.
The company’s clinical interpretation, performed across 347 different cancer subtypes, including solid tumors and hematologic malignancies, has shown clinically actionable results, including:
- In more than 70% of cases, N-of-One®’s clinical interpretation revealed that there are significant therapeutic options available beyond the current standard of care.
In the hundreds of direct patient cases that N-of-One®
has followed through treatment, approximately 35% of treating
physicians made an immediate change to their therapeutic strategy
after they received the N-of-One® clinical
- Of this cohort, 25% were interested in pursuing a clinical trial. The interpretation of molecular data for this cohort has led to the identification of clinical trials in 96% of interested patients. The enrollment rates for the group interested in a clinical trial was approximately 38%, and was 9.5% out of the total population of patients we followed. These rates are well above the national average of 3%.
N-of-One® has provided relevant clinical and scientific knowledge for next-generation sequencing tests and other molecular diagnostic tests for the tumors of thousands of cancer patients by serving as a key provider of clinical interpretation for leading cancer diagnostics companies including Foundation Medicine Inc. (FMI), hospital networks such as Fox Chase Cancer Center, and clinical research organizations (CROs), as well as directly to oncologists and their patients. “With the growing importance of clinical interpretation we have added and are in discussion with a number of healthcare providers and diagnostics companies to provide clinical interpretation of their next generation sequencing tests,” said Chris Cournoyer, CEO of N-of-One®.
“Our relationship with Foundation Medicine is a great example of how we have historically been able to get our clinical interpretation of molecular diagnostics tests into the hands of thousands of treating physicians,” Cournoyer said.
“We produced 1,830 clinical interpretation reports in 2012, and year-to-date in 2013, we produced 2,237 reports for our partners, which include Foundation Medicine Inc., Fox Chase Cancer Center and others. N-of-One’s clinical interpretation is now being distributed to thousands of physicians, making N-of-One® the critical link between sequencing and valuable clinical insight on available therapeutic strategies,” Cournoyer said.
“When oncologists have exhausted the standard of care protocols they do make changes to the therapeutic strategy when they have access to these molecularly guided therapeutic strategies in the clinical setting,” said Dr. Jennifer Levin Carter, Chief Medical Officer of N-of-One®. “Through N-of-One®, it is now possible for oncologists and their patients to take advantage of next-generation sequencing and other molecular diagnostics to identify therapeutic options that are specifically suited to each patient and beyond the standard of care.”
N-of-One Therapeutics, Inc., a leader in precision medicine, leverages its world-class team of experts to translate molecular data specific to each patient into state-of-the-art, clinically actionable insights and therapeutic options focused on the point of care. Using the company’s PrecisionWorks® knowledge integration platform and framework, N-of-One®’s team of experts has interpreted next-generation sequencing and other molecular diagnostics tests of tumors and delivered thousands of personalized, interpretative roadmaps to oncologists and patients worldwide, either directly, through partnerships to provide interpretation services for leading diagnostic companies or through agreements with provider networks.
N-of-One® solutions and services can incorporate data from any sequencing platform, diagnostic or bioinformatics system. PrecisionWorks® also powers solutions that address the unique logistical and procedural challenges of delivering personalized cancer care by streamlining coordination among health care providers, diagnostic companies, drug and technology innovators and payers. N-of-One® does not provide medical advice or promote any product or service. For more information, please visit www.n-of-one.com or call 617-202-9808.